Although these other pathways seem to influence inflammatory processes, the NLRP3 inflammasome, IL-1β, and IL-18 levels are still the main targets used to identify potential molecules inhibitors in LN and kidney diseases [51,61,62]. This evidence concerns the gene IL18 and lobular neoplasia.